Volume 14, Issue 1 (Winter 2023)
Caspian J Intern Med 2023, 14(1): 23-30 |
Back to browse issues page
Shiva Rahimi-Dehgolan 
, Maryam Masoudi , Shahram Rahimi-Dehgolan , Amir Reza Azimi , Mohammad Ali Sahraian , Seyed Mohammad Baghbanian , Abdorreza Naser Moghadasi *
, Maryam Masoudi , Shahram Rahimi-Dehgolan , Amir Reza Azimi , Mohammad Ali Sahraian , Seyed Mohammad Baghbanian , Abdorreza Naser Moghadasi *
Multiple Sclerosis Research Center, Neuroscience Institute, Tehran University of Medical sciences, Tehran, Iran , abdorrezamoghadasi@gmail.com
Abstract: (1642 Views)
Background: Optic neuritis (ON) is one of the main neuro-ophthalmic presentations of multiple sclerosis (MS), and it causes optic nerve atrophy and axonal loss. However, so far, there is no effective treatment to improve long-term outcomes.
Methods: In a double-blind placebo-controlled randomized clinical trial, 50 patients with MS-related ON were allocated into two arms (24 in the control group and 26 in the intervention group) receiving either 25000IU retinyl palmitate or an identical placebo for six months. Visual evoked potential (VEP), visual acuity, and the retinal nerve fiber layer (RNFL) thickness were evaluated and compared before and after the treatment.
Results: RNFL thickness reduction in the affected eyes at sixth month compared to the baseline were 14.81 and 19.46 μm, in the intervention and control groups, respectively (P=0.017). However, VitA therapy did not affect visual acuity and VEP.
Conclusion: Vitamin A supplementation in the patients with acute ON in MS could lessen optic nerve axonal loss.
Methods: In a double-blind placebo-controlled randomized clinical trial, 50 patients with MS-related ON were allocated into two arms (24 in the control group and 26 in the intervention group) receiving either 25000IU retinyl palmitate or an identical placebo for six months. Visual evoked potential (VEP), visual acuity, and the retinal nerve fiber layer (RNFL) thickness were evaluated and compared before and after the treatment.
Results: RNFL thickness reduction in the affected eyes at sixth month compared to the baseline were 14.81 and 19.46 μm, in the intervention and control groups, respectively (P=0.017). However, VitA therapy did not affect visual acuity and VEP.
Conclusion: Vitamin A supplementation in the patients with acute ON in MS could lessen optic nerve axonal loss.
Type of Study: Original Article |
Subject:
Neurology
Received: 2021/08/25 | Accepted: 2021/12/6 | Published: 2023/01/11
Received: 2021/08/25 | Accepted: 2021/12/6 | Published: 2023/01/11
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |